LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
Radiation dermatitis is a common side-effect of radiation therapy in cancer patients who frequently can experience redness, pain, crusting, and even ulceration of the skin causing suffering and treatment interruption. A recent retrospective study by DeLand demonstrated that administering light emitting diode (LED) photomodulation after each radiation treatment for breast cancer decreased radiation dermatitis in a majority of patients. LED photomodulation is a process by which specific sequences of light are used to regulate or manipulate cell activity without causing heat or damage to the skin. Each LED treatment is painless and is completed in usually less than one minute. LED photomodulation may reduce the suffering associated with radiation treatments, improve cosmetic outcome in radiation fields, and eliminate breaks in radiation treatments which may be required because of severe ulcerating reactions.
This study will attempt to replicate the findings of Dr. DeLand's study by randomly assigning at least 40 breast cancer patients to either a treatment group or to a control group. The treatment group will receive LED photomodulation treatments before and after each radiation treatment with the Gentlewaves Select™ handheld high energy 590nm LED array using specific sequences of pulses used in other studies; the treatment group will also receive 7 additional treatments over 2 weeks after their radiation treatment course is completed. The control group will receive no LED treatment but will use the exact same skin care regimen as the treatment group. In addition to weekly evaluation and grading of skin reactions, subjects will be photographed under standardized conditions weekly and then photographs will be evaluated and graded by blinded dermatologists.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Subjects must have clinically diagnosed breast or head and neck cancer that will be treated with radiation therapy.
- Subjects must be at least 18 years of age
Exclusion criteria
- Subjects will not be eligible to participate if they are pregnant or lactating.
- Patients treated with partial breast irradiation techniques, brachytherapy, or other non-standard techniques will not be eligible.
Trial design
Primary purpose
Allocation
Interventional model
Masking
33 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal